Idelalisib- a PI3Kδ targeting agent for B-cell malignancies

Journal of Oncology Pharmacy Practice

Volumn 22, Issue 2, 2016, Pages 284-288

  Hewett, Yvonne G ^a   Uprety, Dipesh ^b   Shah, Binay K ^a  

^a St Joseph Regional Cancer Center   (United States)

^b ABINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

Idelalisib; lymphoma; PI3K inhibitor

Indexed keywords

IDELALISIB; PLACEBO; RITUXIMAB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CD PROTEIN, MOUSE; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; FOLLICULAR LYMPHOMA; HUMAN; LYMPHOCYTOMA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; REVIEW; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PURINES; QUINAZOLINONES;

EID: 84959296840     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155215572933     Document Type: Review

References (25)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™: Non-Hodgkin's Lymphomas [v.1.2015]. http://www.nccn.org/professionals/physician-gls/PDF/nhl.pdf (accessed 12 January 2015).
2. Veliz M, Pinilla-Ibarz J,. Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control 2012; 19 (1): 37-53.
3. Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81 (11): 2878-2884.
4. Burris HA 3rd,. Overcoming acquired resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013; 71 (4): 829-842.
5. Miller TW, Balko JM, Arteaga CL,. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011; 29 (33): 4452-4461.
6. Macias-Perez IM, Flinn IW,. GS-1101: A delta-specific PI3K inhibitor in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2013; 8 (1): 22-27.
7. Chang JE, Kahl BS,. PI3-kinase inhibitors in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2014; 9 (1): 33-43.
8. Norman P,. Selective PI3Kδ inhibitors, a review of the patent literature. Expert Opin Ther Pat 2011; 21 (11): 1773-1790.
9. Chantry D, Vojtek A, Kashishian A, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997; 272 (31): 19236-19241.
10. Kahl BS, Spurgeon SE, Furman RR, et al. Results of a phase I study of idelalisib, a PI3Kδ inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL). Blood 2014.
11. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014.
12. Akinleye A, Avvaru P, Furqan M, et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol 2013; 6 (1): 88-88.
13. Lopez JP, Jimeno A,. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma. Drugs Today (Barc) 2014; 50 (2): 113-120.
14. Bononi A, Agnoletto C, DeMarchi E, et al. Protein kinases and phosphatases in the control of cell fate. Enzyme Res 2011; 2011: 329098-329098.
15. Zydelig [package insert], Foster City, CA: Gilead Sciences, Inc., 2014.
16. Jin F, Robeson M, Zhou H, et al. Pharmacokinetics, metabolism, and excretion of idelalisib. Blood (ASH Annual Meeting Abstracts) 2013; 122. Abstract 5570. Published ahead of print 6 Dec 2013.
17. Jin F, Robeson M, Zhou H, et al. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. Blood (ASH Annual Meeting Abstracts) 2013; 122. Abstract 5571. Published ahead of print 6 Dec 2013.
18. Jin F, Robeson M, Zhou H, et al. the pharmacokinetics and safety of idelalisib in subjects with severe renal impairment. Blood (ASH Annual Meeting Abstracts) 2013; 122. Abstract 5572. Published ahead of print 6 Dec 2013.
19. Jin F, Robeson M, Zhou H, et al. Evaluation of the effect of idelalisib on the QT/QTc interval in healthy subjects. Blood (ASH Annual Meeting Abstracts) 2013; 122. Abstract 5573. Published ahead of print 6 Dec 2013.
20. Jin F, Robeson M, Zhou H, et al. Evaluation of drug interaction profile of idelalisib and its major circulating metabolite, GS-563117, in healthy subjects. Blood (ASH Annual Meeting Abstracts) 2013; 122. Abstract 5574. Published ahead of print 6 Dec 2103.
21. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014.
22. Coutre SE, Leonard JP, Furman RR, et al. Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Results from a phase I study. Blood (ASH Annual Meeting Abstracts) 2012; 120. Abstract 191.
23. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370 (11): 1008-1018.
24. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370 (11): 997-1007.
25. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111. 5446-5456.